Recce Pharmaceuticals - Taking a closer look at diabetic foot infections
We highlight the opportunity of topical RECCE® 327 (R327) to address diabetic foot infections (DFIs), which is the leading cause of limb morbidity...
189 Views
Recce Pharmaceuticals - Advances on several fronts
Recce Pharmaceuticals has reported several encouraging developments in recent weeks for its lead development compound RECCE® 327 (R327). The...
172 Views
Recce Pharmaceuticals - R&D advance (A$11.18m) extends runway
Recce Pharmaceuticals recently received A$11.18m as an R&D advance credit through an arrangement with Endpoints Capital for the R&D tax...
223 Views
Recce Pharmaceuticals - Supportive advancements on the pipeline
Recce Pharmaceuticals has announced several positive developments in recent weeks relating to its therapeutic programmes, particularly for lead...
211 Views
Recce Pharmaceuticals - Landmark commitment helps fund R&D costs
Recce recently reported that the Australian government has committed to providing up to A$55m in future cash rebates to reimburse upcoming R&D...
298 Views